溶瘤病毒在肿瘤治疗策略中的创新与挑战OA
Innovations and challenges of oncolytic viruses in cancer treatment strategies
溶瘤病毒(OVs)作为肿瘤免疫治疗的创新策略,以其治疗的高效性、肿瘤的精准靶向以及相对较低的副作用,正日益展现出其在癌症治疗中的显著潜力.本文全面综述了OVs治疗策略的演变历程、科学基础、通过基因工程进行的改造、临床应用的策略,以及OVs与其他治疗手段联合使用的协同效应潜力.同时,讨论了OVs在临床转化过程中所面临的挑战,包括安全性、疗效评估、病毒载体的选择等问题.此外,本文还介绍了几种已经商业化的OVs药物,包括H101、T-VEC和Delytact,它们在多种肿瘤治疗中显示出积极疗效.本文旨在探讨OVs在肿瘤治疗中的创新应用及其面临的挑战,为免疫学和肿瘤学领域的科研工作者提供全面视角,以推动该疗法的科研发展和临床应用.
Oncolytic viruses(OVs),as an innovative strategy for cancer immunotherapy,are increasingly demonstrating sig-nificant potential in cancer treatment due to their high efficacy,precise tumor targeting,and relatively low side effects.This article provides a comprehensive review of the evolution of OV treatment strategies,scientific foundations,genetic engineering modifica-tions,clinical application strategies,and the potential for synergistic effects when used in combination with other therapeutic ap-proaches.It also discusses the challenges faced by OVs in the clinical translation process,including safety,efficacy assessment,and selection of viral vectors.In addition,the article introduces several commercialized OV drugs,such as H101,T-VEC and Delytact,which have shown positive therapeutic effects in the treatment of various types of cancer.The aim of this article is to explore innovative applications of OVs in cancer treatment and the challenges they face,providing a comprehensive perspective for researchers in the fields of immunology and oncology,in order to promote the scientific development and clinical application of this therapy.
张典;汪洋;李建全;高兴春
西安医学院基础医学部免疫教研室,西安 710021西安医学院基础医学部微生物教研室,西安 710021西京学院计算机学院,西安 710100西安医学院基础医学部免疫教研室,西安 710021
医药卫生
溶瘤病毒肿瘤免疫治疗治疗挑战基因工程改造
Oncolytic virusesCancer immunotherapyTherapeutic challengesGenetic engineering modification
《中国免疫学杂志》 2026 (4)
997-1002,6
国家自然科学基金面上项目(11971281).
评论